Economic evaluation of targeted cancer interventions: Critical review and recommendations

Genetics in Medicine

Volumn 13, Issue 10, 2011, Pages 853-860

  Elkin, Elena B ^a   Marshall, Deborah A ^b,c   Kulin, Nathalie A ^b   Ferrusi, Ilia L ^c   Hassett, Michael J ^d   Ladabaum, Uri ^e   Phillips, Kathryn A ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Stanford California and Cofounder   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA; breast cancer; cost effectiveness analysis; economic analysis; gene expression profiling; personalized medicine; targeted therapy; trastuzumab

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RALOXIFENE; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; GENE MUTATION; GENETIC ASSOCIATION; HEALTH CARE COST; HUMAN; REVIEW; RISK REDUCTION;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RISK REDUCTION BEHAVIOR;

EID: 80053907936     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31821f3e64     Document Type: Review

References (67)

1. Neumann PJ. Costing and perspective in published cost-effectiveness analysis. Med Care 2009;47:S28-S32.
2. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 2005.
3. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
4. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006.
5. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130. (Pubitemid 36530000)
6. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886. (Pubitemid 20026073)
7. Jacobi CE, de Bock GH, Siegerink B, et al. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 2009;115:381-390.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388. (Pubitemid 28439961)
9. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 2006;295:2727-2741.
10. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337.
11. Olopade OI, Artioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 2004;10(suppl 1): S5-S9. (Pubitemid 38141762)
12. Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. J Am Med Assoc 2008;299:2151-2163. (Pubitemid 351679706)
13. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007;356:1295-1303. (Pubitemid 46513295)
14. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353:1773-1783. (Pubitemid 41549889)
15. Hershman D, Sundararajan V, Jacobson JS, et al. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 2002;20:9-16. (Pubitemid 34032590)
16. Noe LL, Becker RV 3rd, Gradishar WJ, et al. The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care 1999;5: S389-S406. (Pubitemid 29296048)
17. Anderson K, Jacobson JS, Heitjan DF, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006;144:397-406. (Pubitemid 46768161)
18. Moore SG, Shenoy PJ, Fanucchi L, et al. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res 2009;9:9.
19. Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. J Am Med Assoc 2006;295:2374-2384. (Pubitemid 43788105)
20. Taneja C, Edelsberg J, Weycker D, et al. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol 2009;6:171-179.
21. Grann VR, Whang W, Jacobson JS, et al. Benefits and costs of screening ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 1999;17:494.
22. Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health 2009;12:207-216.
23. Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010;28: 4214-4220.
24. Grann V, Patel P, Jacobson J, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 2011;125:837-847.
25. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
26. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Pubitemid 19147683)
27. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
28. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684. (Pubitemid 41464706)
29. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
30. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, 2011. Available at: http://www.nccn.org/professionals/physician- gls/PDF/breast.pdf. Accessed April 26, 2011.
31. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
32. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004;22:854-863. (Pubitemid 41103597)
33. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005;16:909-914. (Pubitemid 40903916)
34. Lidgren M, Jonsson B, Rehnberg C, et al. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008;19:487-495. (Pubitemid 351325669)
35. Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007;25:634-641. (Pubitemid 350002917)
36. Dendukuri N, Khetani K, McIsaac M, et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007; 176:1429-1434. (Pubitemid 46762020)
37. Garrison LP, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007;110:489-498. (Pubitemid 47106136)
38. Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/neu-positive breast cancer: an analysis based on updated results from the HERA trial. Value Health 2009;12:641-648.
39. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007;25:625-633. (Pubitemid 350002916)
40. Norum J, Olsen JA, Wist EA, et al. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol 2007;46: 153-164.
41. National Institutes for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of earlystage HER2-positive breast cancer. NICE technology appraisal guidance; London, UK, 2006. Available at: http://www.nice.org.uk/nicemedia/live/11586/33458/33458.pdf. Accessed January 1, 2011.
42. Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics 2007;25:429-442. (Pubitemid 46744472)
43. Dedes KJ, Szucs TD, Imesch P, et al. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 2007;18:1493-1499. (Pubitemid 47365481)
44. Neyt M, Huybrechts M, Hulstaert F, et al. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 2008;87:146-159.
45. Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 2008;109:559-566. (Pubitemid 351692065)
46. Chen W, Jiang Z, Shao Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health 2009;12(suppl 3):S82-S84.
47. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005;11:313-324. (Pubitemid 40646936)
48. Lyman GH, Cosler LE, Kuderer NM, et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007;109:1011-1018. (Pubitemid 46435378)
49. Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest 2009;27:953-959.
50. Klang SH, Hammerman A, Liebermann N, et al. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 2010;13:381-387.
51. Tsoi DT, Inoue M, Kelly CM, et al. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 2010;15:457-465.
52. Oestreicher N, Ramsey SD, Linden HM, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 2005;7:380-389. (Pubitemid 41139621)
53. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
54. Hunink M, Glasziou P, Siegel J, et al. Decision making in health and medicine: integrating evidence and values. Cambridge, UK: Cambridge University Press, 2001.
55. Marshall DA, O'Brien BJ. Economic evaluation of diagnostic tests. In: Price C, Christenson R, editors. Evidence-based laboratory medicine: from principles to outcomes. Washington, DC: American Association for Clinical Chemistry, 2003:159-186.
56. Elkin EB, Bach PB. Cancer's next frontier: addressing high and increasing costs. J Am Med Assoc 2010;303:1086-1087.
57. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J Am Med Assoc 2009;302:1429-1436.
58. Punglia RS, Burstein HJ, Winer EP, et al. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008;100:642-648.
59. Chang-Claude J, Ambrosone CB, Lilla C, et al. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 2009;100:1680-1686.
60. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-1860.
61. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-269. (Pubitemid 43113031)
62. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. J Am Med Assoc 2006;296:1507-1517. (Pubitemid 44465515)
63. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823-827. (Pubitemid 27132979)
64. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
65. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006;106:1007-1016.
66. American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 2008;148:956-961.
67. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009; 27:3868-3874.